Inhibition of olig2 activity

A compound having the structure of Formula (I):

• wherein:
• A is a bond, O, CH2, or N(R10);
• X, Y, and Z are each independently N, or C(R7);
• each R1 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SR8, —N(R8)S(═O)2R9, —S(═O)2N(R8)2, —S(═O)R9, —S(═O)2R9, —C(═O)R9, —CO2R8, —N(R8)2, —C(═O)N(R8)2, —NR8)C(═O)R9, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C6-C10aryl, or substituted or unsubstituted C2-C7heteroaryl;
• or two R1 are taken together to form a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted carbocyclic ring;
• R2, R3, and R4 are each independently H, —CN, C1-C4alkyl, C3-C6cycloalkyl, or C2-C7heterocycloalkyl;
• or two of R2, R3, and R4 are taken together to form a 5- or 6-membered heterocyclic ring;
• R5 is halogen, —CN, —OH, —CF3, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C6-C10aryl, or substituted or unsubstituted C2-C7heteroaryl;
• R6 is substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C2-C7heteroaryl, —(C(R14)(R15))mR21, —(C(R14)(R15))mN(R11)(R12), or
• R11 and R12 are each independently H, or substituted or unsubstituted C1-C6alkyl;
• or R11 and R12 are taken together to form a 5-, 6-, 7-, or 8-membered heterocyclic ring;
• J is C(H), or N;
• R13 is H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted —C1-C4alkylC6-C10aryl, or substituted or unsubstituted —C1-C4alkylC2-C7heteroaryl;
• each R7 is independently H, halogen, —CN, —OH, —CF3, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C6-C10aryl, or substituted or unsubstituted C2-C7heteroaryl;
• each R14 and R15 are each independently H, or substituted or unsubstituted C1-C6alkyl;
• or R14 and R15 are taken together to form a 4-, 5-, 6-membered cycloalkyl ring;
• R21 is halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SR22, —N(R22)S(═O)2R23, —S(═O)2N(R22)2, —S(═O)R23, —S(═O)2R23, —C(═O)R23, —CO2R22, —C(═O)N(R22)2, —N(R22)C(═O)R23, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C6-C10aryl, or substituted or unsubstituted C2-C7heteroaryl;
• each R22 is independently H, or substituted or unsubstituted C1-C6alkyl;
• R23 is substituted or unsubstituted C1-C6alkyl;
• each R8 is independently H, or substituted or unsubstituted C1-C6alkyl;
• R9 is substituted or unsubstituted C1-C6alkyl;
• R10 is H, or C1-C4alkyl;
• m is 2-6;
• n is 0-5;
• p is 1-3;
• q is 1-3;
• or
• a pharmaceutically acceptable salt, solvate, or prodrug thereof.